SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Delivery formulations

News headlines

Mylan confirms plan to close Meda Soma plant in Illinois

28-Mar-2017 - Mylan will close a manufacturing site in Decatur, Illinois that it gained when it bought Swedish drug maker Meda last year.

Alexion licenses mRNA delivery tech from Arbutus in potential $82.5m deal

27-Mar-2017 - Alexion Pharmaceuticals will use the LNP delivery licensed from Arbutus Biopharma as part of its messenger RNA therapeutics development partnership with Moderna Therapeutics.

Compounding firm looks at NDA opportunity for reformulation of Mallinckrodt's H.P. Acthar

23-Mar-2017 - Imprimis Pharmaceuticals says it is evaluating pursuing New Drug Application (NDA) status for some of its product reformulations through the US FDA 505(b)(2) development pathway.

Pulmatrix secures EU patent for dry powder delivery tech

22-Mar-2017 - Pulmatrix Inc has extended its IP portfolio with a European patent for its particle-based drug delivery technology.

Cannabinoid-based chewing gum enrolls patients in Ph II trial

16-Mar-2017 - Axim Biotech has enrolled patients in its Phase II trial for Canchew Plus chewing gum – a delivery method with a “cumulative effect,” says CEO.

Heptares, Daiichi Sankyo to develop small molecules for pain treatment

15-Mar-2017 - Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo – providing further validation of the company’s structure-based drug design approach, says CEO.

Opioid API firm Noramco moves into cannabinoids

08-Mar-2017 - Noramco has added cannabinoids to its portfolio of opioid APIs.

Noramco planning formulation tech unit alongside opioid API business

07-Mar-2017 - Former J&J controlled substance API unit Noramco is to rejig its business to cater for branded and generic drug firms and companies looking for formulation tech solutions.

update

Wockhardt says Ireland's HPRA has recommended GMP cert renewal for Shendra site

07-Mar-2017 - Wockhardt says Irish regulators have recommended renewal of its Shendra, Aurangabad facility's GMP certificate.

US FDA says Wockhardt's oversight of drug production inadequate

07-Mar-2017 - The US FDA has told Wockhardt its quality issues are company-wide, citing problems at subsidiary Morton Grove as an example in a warning letter published today.

US FDA lifts hold on Seattle Genetics' blood cancer ADC candidate

07-Mar-2017 - The US FDA has cleared Seattle Genetics to restart trials of its blood cancer candidate vadastuximab talirine that were halted last year after patient deaths. 

Vaxess granted $6m to develop sustained release vaccine patches

07-Mar-2017 - Two Bill & Melinda Gates Foundation grants will be used to develop a polio and measles rubella vaccine delivered through microneedles on a sustained-dermal patch.

Nemus hires Catalent to formulate second chemo-induced nausea drug

06-Mar-2017 - Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.

Keryx: Patheon and Norwich sites will ensure supply of iron-based Auryxia

06-Mar-2017 - Keryx Biopharmaceuticals will continue to work with Norwich Pharmaceuticals despite bringing Patheon on board to manufacture Auryxia (ferric citrate).

Turmeric bioavailability enhancer could be used with APIs, Wacker

02-Mar-2017 - Wacker Biosolutions says an excipient shown to increase the bioavailability of a food supplement by a factor of 40 could have implications in the API space.

Titan puts Parkinson's disease implant trial on hold after FDA asks for more data

28-Feb-2017 - Titan Pharmaceuticals has put plans for a trial of its candidate Parkinson’s disease implant ropinirole after the US FDA asked for additional information.

Ohr Pharmaceutical Inc. shuts sustained release tech lab

23-Feb-2017 - Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.

Modus raises cash for Ph II trial of Sickle Cell drug in EU, Middle East and Caribbean

22-Feb-2017 - Modus Therapeutics AB has raised an additional 32m SEK (£2.85m) for its Phase II trial for pain crises in Sickle Cell Disease, running in the Caribbean, Middle East and Europe.

Granules to expand Indian API plants and US dosage form site

21-Feb-2017 - Granules India will build an API production facility in Bonthapally, Telangana and expand other manufacturing sites in a project backed by the Word Bank. 

Tilray begins shipping medical marijuana to more countries

20-Feb-2017 - Medical marijuana developer Tilray has begun shipping to overseas patients and trial sites outside Canada after partnering with local distributors to comply with regional regulations.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...